Kyle Piskel Sells 3,115 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 3,115 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total value of $40,619.60. Following the sale, the chief financial officer owned 256,725 shares in the company, valued at $3,347,694. The trade was a 1.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kyle Piskel also recently made the following trade(s):

• On Wednesday, March 11th, Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total value of $245,910.24.

Adaptive Biotechnologies Stock Down 0.6%

Shares of Adaptive Biotechnologies stock opened at $13.87 on Friday. The stock’s fifty day moving average is $13.79 and its two-hundred day moving average is $15.63. The company has a market capitalization of $2.22 billion, a PE ratio of -42.03 and a beta of 2.16. Adaptive Biotechnologies Corporation has a 52 week low of $8.50 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.20) EPS. As a group, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently added to or reduced their stakes in ADPT. Westfield Capital Management Co. LP bought a new stake in Adaptive Biotechnologies during the fourth quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD boosted its position in Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Invesco Ltd. boosted its position in Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after purchasing an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on ADPT shares. Morgan Stanley cut their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. TD Cowen increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. BTIG Research reissued a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.